Selective peptide-based β-catenin Degrader (PROTAC™)
xStAx-VHLL is a selective peptide-based β-catenin Degrader (PROTAC™). Comprises a β-catenin-targeted stapled peptide, xStAx, linked to a VHL-binding peptide. Reduces β-catenin levels in HEK293T cells and colorectal cancer cell lines. Selectively degrades β-catenin over other Wnt signaling pathway components. Inhibits tumor growth in
APCmin/+
mice, with constitutively active Wnt signaling, and reduces survival of patient-derived colorectal cancer cell organoids.
PROTAC™ is a registered trademark of Arvinas Operations, Inc., and is used under license
| Marque | Tocris |
|---|---|
| Réf. B-LABO | BL-RE-158188 |
| Réf. fabricant | 18767016 |
| Quantité | 100 μg |
| Cible | Active Degraders |
| Formule moléculaire | C<sub>154</sub>H<sub>244</sub>N<sub>48</sub>O<sub>29</sub> |
| Pureté | 0.95 |
